Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Avacta Group PLC

AVCT
Current price
50 GBX +0.5 GBX (+1.01%)
Last closed 48.45 GBX
ISIN GB00BYYW9G87
Sector Healthcare
Industry Biotechnology
Exchange London Exchange
Capitalization 190 756 431 GBX
Yield for 12 month -65.75 %
1Y
3Y
5Y
10Y
15Y
AVCT
21.11.2021 - 28.11.2021

Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells. It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom. Address: Thorp Arch Estate, Wetherby, United Kingdom, LS23 7FA

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4 596.83 GBX

P/E ratio

Dividend Yield

Current Year

+2 326 699 693 GBX

Last Year

+966 130 315 GBX

Current Quarter

+1 127 068 635 GBX

Last Quarter

+1 136 776 979 GBX

Current Year

+757 951 445 GBX

Last Year

+423 463 971 GBX

Current Quarter

+305 562 615 GBX

Last Quarter

+449 986 737 GBX

Key Figures AVCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -28 541 507 GBX
Operating Margin TTM -136.12 %
PE Ratio
Return On Assets TTM -21.8 %
PEG Ratio
Return On Equity TTM -73.02 %
Wall Street Target Price 4 596.83 GBX
Revenue TTM 22 638 457 GBX
Book Value 0.14 GBX
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -5.3 %
Dividend Yield
Gross Profit TTM 6 198 327 GBX
Earnings per share -0.09 GBX
Diluted Eps TTM -0.09 GBX
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -114.45 %

Dividend Analytics AVCT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AVCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:100
Payout Ratio
Last Split Date 26.01.2016
Dividend Date

Stock Valuation AVCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 8.2948
Price Sales TTM 8.4262
Enterprise Value EBITDA -12.0368
Price Book MRQ 4.1095

Financials AVCT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AVCT

For 52 weeks

39.53 GBX 152.13 GBX
50 Day MA 61.27 GBX
Shares Short Prior Month
200 Day MA 61.25 GBX
Short Ratio
Shares Short
Short Percent